At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 59 enrolled
Drug / intervention
Avastin (bevacizumab) +2 moredrug
Likely dose
Avastin (bevacizumab) 10 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of the Anti-Vascular Endothelial Growth Factor (α-VEGF) Monoclonal Antibody Bevacizumab in Combination With Fixed Dose Rate (FDR) Gemcitabine and Rapid-Fractionation Radiotherapy in the Pre-operative Treatment of Potentially- Resectable Pancreatic Adenocarcinoma
In Brief
A Phase 2 clinical trial evaluating Avastin (bevacizumab), Gemzar (Gemcitabine), and 1 other intervention for Pancreatic Cancer. Completed, enrolled 59 participants across 1 site.
Detailed Summary
This study is to determine the efficacy of bevacizumab and gemcitabine in combination with radiation therapy in the preoperative treatment of potentially-resectable subjects with pancreatic cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2006
First PostedNov 2007
Primary CompletionMar 2012
Study CompletionDec 2016
TodayJul 2026
First PostedNov 14, 2007
Enrollment StartDec 1, 2006
Primary CompletionMar 1, 2012
Study CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 18.6 years ago
Interventions
Avastin (bevacizumab)drug
10 mg/kg, days 1, 15, 29 and 43
Gemzar (Gemcitabine)drug
On days 1, 15, and 29, subjects will receive gemcitabine 1500 mg/m2 IV over 150 minutes at the fixed-dose rate (10 mg/m2/min).
external beam radiotherapyradiation
3 Gy/fraction utilizing a 95% isodose field over 10 consecutive weekdays, Monday to Friday, for a total of 30 Gy